• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody

tetano

Editor, Senior Moderator
PLoS Pathog. 2019 Jan 3;15(1):e1007427. doi: 10.1371/journal.ppat.1007427. eCollection 2019 Jan.
[h=1]IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody.[/h] Saito S[SUP]1,[/SUP][SUP]2[/SUP], Sano K[SUP]1,[/SUP][SUP]3[/SUP], Suzuki T[SUP]1[/SUP], Ainai A[SUP]1[/SUP], Taga Y[SUP]4[/SUP], Ueno T[SUP]4[/SUP], Tabata K[SUP]1[/SUP], Saito K[SUP]1[/SUP], Wada Y[SUP]1[/SUP], Ohara Y[SUP]1[/SUP], Takeyama H[SUP]5[/SUP], Odagiri T[SUP]2[/SUP], Kageyama T[SUP]2[/SUP], Ogawa-Goto K[SUP]4[/SUP], Multihartina P[SUP]6[/SUP], Setiawaty V[SUP]6[/SUP], Pangesti KNA[SUP]6[/SUP], Hasegawa H[SUP]1,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Mucosal immunoglobulins comprise mainly secretory IgA antibodies (SIgAs), which are the major contributor to pathogen-specific immune responses in mucosal tissues. These SIgAs are highly heterogeneous in terms of their quaternary structure. A recent report shows that the polymerization status of SIgA defines their functionality in the human upper respiratory mucosa. Higher order polymerization of SIgA (i.e., tetramers) leads to a marked increase in neutralizing activity against influenza viruses. However, the precise molecular mechanisms underlying the effects of SIgA polymerization remain elusive. Here, we developed a method for generating recombinant tetrameric monoclonal SIgAs. We then compared the anti-viral activities of these tetrameric SIgAs, which possessed variable regions identical to that of a broadly neutralizing anti-influenza antibody F045-092 against influenza A viruses, with that of monomeric IgG or IgA. The tetrameric SIgA showed anti-viral inhibitory activity superior to that of other forms only when the antibody exhibits low-affinity binding to the target. By contrast, SIgA tetramerization did not substantially modify anti-viral activity against targets with high-affinity binding. Taken together, the data suggest that tetramerization of SIgA improved target breadth, but not peak potency of antiviral functions of the broadly neutralizing anti-influenza antibody. This phenomenon presumably represents one of the mechanisms by which SIgAs present in human respiratory mucosa prevent infection by antigen-drifted influenza viruses. Understanding the mechanisms involved in cross neutralization of viruses by SIgAs might facilitate the development of vaccine strategies against viral infection of mucosal tissues.


PMID: 30605488 DOI: 10.1371/journal.ppat.1007427
Free full text
 
Back
Top Bottom